Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594827 | 0.88 | AR (0.54) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL3289362 | 0.80 | AR (0.55) | ARPGRTAS2R14SLC22A12 | |
| SCHEMBL4595644 | 0.79 | TAS2R14 (0.52) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL19976340 | 0.78 | AR (0.50) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1291418 | 0.78 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL12140104 | 0.78 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1363920 | 0.78 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1363115 | 0.78 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL4903763 | 0.78 | AR (0.46) | ARPGR | |
| SCHEMBL4903311 | 0.77 | AR (0.52) | ARPGRTAS2R14SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | AR 84/4885PGR 64/4885TAS2R14 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.